Sign in Subscribe
Cancer research

Novel Therapy Options for Antimicrobial Resistance: New Study Provides Insights on Curcumin Liposomes

Strategic Insights

— 1 min read

A recent study published in the European Journal of Pharmaceutical Sciences has shed new light on the development of novel therapy options to address antimicrobial resistance (AMR). Researchers from Philipps-Universität Marburg have investigated the potential of curcumin-loaded liposomes as a treatment for pulmonary infections caused by gram-positive bacteria. The study highlights the importance of overcoming AMR and the promising approach offered by positively charged curcumin liposomes.

Key Takeaways:

  • The inappropriate use of antibiotics over the last few decades has led to antimicrobial resistance (AMR), where bacteria no longer respond to common antibiotics.
  • Positively charged curcumin (Cur)-loaded liposomes, specifically Cur-DOTAP liposomes, offer a promising approach to addressing lung infections caused by gram-positive bacteria.
  • The physicochemical properties of the liposomes do not affect the antimicrobial photodynamic efficacy, but the lamellarity of the liposomes does.
  • The study demonstrated a substantial reduction in bacterial viability of more than 5.7 log for unilamellar vesicles (ULVs) and 3.9 log for multilamellar vesicles (MLVs).
  • Positive surface charge of the liposomes allows them to be absorbed onto the negatively charged bacterial surface through electrostatic interactions.
  • The biocompatibility of the liposomes was confirmed in vitro with mouse connective tissue fibroblasts (L929) and in ovo using the chorioallantoic membrane (CAM) model.

Statistics:

  • The study reported a maximum reduction in bacterial viability of 3.9 log.
  • A substantial reduction in bacterial viability of more than 5.7 log was determined for ULVs only.
  • The study demonstrated the ability to treat pulmonary infections caused by gram-positive bacteria.

Sources:

  • "Optimizing the antimicrobial photodynamic efficacy of curcumin liposomes to treat pulmonary infections caused by gram-positive bacteria." European Journal of Pharmaceutical Sciences, 2025:107311.
  • European Journal of Pharmaceutical Sciences. Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • Philipps-Universität Marburg. Dept. of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Robert-Koch-Str. 4, 35037 Marburg, Germany.

Read more